Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer
Sponsor: Human Genome Center, Institute of Medical Science, University of Tokyo
Terminated
Lack of financial support
Other terminated trials from Human Genome Center, Institute of Medical Science, University of Tokyo
- Breast Cancer · Phase PHASE1/PHASE2 · May 2009
- Pancreas Neoplasms · Phase PHASE1/PHASE2 · May 2009
- Colon Cancer · Phase PHASE1/PHASE2 · Mar 2009
- Breast Cancer · Phase PHASE1/PHASE2 · Mar 2009
See all terminations from Human Genome Center, Institute of Medical Science, University of Tokyo
Other Colon Cancer trials with similar outcome
A PHASE1/PHASE2 clinical study on Colon Cancer and Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Human Genome Center, Institute of Medical Science, University of Tokyo and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Human Genome Center, Institute of Medical Science, University of Tokyo
- Tokyo University
For direct contact, visit the study record on ClinicalTrials.gov .